We have located links that may give you full text access.
Effectiveness and tolerability of tapentadol sustained release in the Australian setting.
Journal of Opioid Management 2016 May
OBJECTIVE: To assess the effectiveness and tolerability of tapentadol sustained release (SR) following its introduction to the Australian private market.
DESIGN: A retrospective audit of routine clinical practice with data collection beginning 2 months after the first tapentadol SR prescription.
SETTING: A multidisciplinary Australian pain clinic.
PATIENTS: Fifty patients who were prescribed tapentadol SR as part of routine clinical management at the pain clinic.
INTERVENTIONS: Trial of tapentadol SR with subsequent dose titration if the patient was satisfied with or tolerant of the medication.
MAIN OUTCOME MEASURES: Patient-reported pain outcome, side effects, medication adherence, and concomitant analgesic medications.
RESULTS: Sixty-eight percent of patients reported major reductions in pain. Seventy-two percent of patients tolerated and adhered to treatment and 76 percent reported no side effects. Pain outcome was independent of pain type and prior opioid exposure; however, patients taking tapentadol in combination were more likely to report a positive outcome (Pearson χ(2) = 9.867, n = 46, p = 0.0072).
CONCLUSIONS: Tapentadol was effective and generally well tolerated in the majority of patients for neuropathic, nociceptive and mixed pain types and this was regardless of prior opioid use.
DESIGN: A retrospective audit of routine clinical practice with data collection beginning 2 months after the first tapentadol SR prescription.
SETTING: A multidisciplinary Australian pain clinic.
PATIENTS: Fifty patients who were prescribed tapentadol SR as part of routine clinical management at the pain clinic.
INTERVENTIONS: Trial of tapentadol SR with subsequent dose titration if the patient was satisfied with or tolerant of the medication.
MAIN OUTCOME MEASURES: Patient-reported pain outcome, side effects, medication adherence, and concomitant analgesic medications.
RESULTS: Sixty-eight percent of patients reported major reductions in pain. Seventy-two percent of patients tolerated and adhered to treatment and 76 percent reported no side effects. Pain outcome was independent of pain type and prior opioid exposure; however, patients taking tapentadol in combination were more likely to report a positive outcome (Pearson χ(2) = 9.867, n = 46, p = 0.0072).
CONCLUSIONS: Tapentadol was effective and generally well tolerated in the majority of patients for neuropathic, nociceptive and mixed pain types and this was regardless of prior opioid use.
Full text links
Trending Papers
A Personalized Approach to the Management of Congestion in Acute Heart Failure.Heart International 2023
Potential Mechanisms of the Protective Effects of the Cardiometabolic Drugs Type-2 Sodium-Glucose Transporter Inhibitors and Glucagon-like Peptide-1 Receptor Agonists in Heart Failure.International Journal of Molecular Sciences 2024 Februrary 21
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app